Leadership
Our team of passionate biopharmaceutical leaders combines deep expertise in drug development and commercialization.
Meet our leadership teamPipeline
We have one of the largest and most diverse pipelines in rare disease.
Explore our pipelineLatest news
View more news >Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
Rare perspective
Insights and information on our approach to collaborating with rare disease communities, supporting our teammates at Ultragenyx, and developing new therapies for rare disease
Read our blog >